| 07/15/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848719279 |
|
| 02/11/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$325.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848707341 |
|
| 12/21/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2640.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848700749 |
|
| 12/23/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2420.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848618293 |
|
| 08/13/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$345.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848617899 |
|
| 04/12/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$670.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848580531 |
|
| 11/03/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$595.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848552689 |
|
| 09/20/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$65.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848552563 |
|
| 01/13/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$475.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848529477 |
|
| 03/08/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$390.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848492809 |
|
| 06/14/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5540.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848472899 |
|
| 05/10/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$390.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848472895 |
|
| 10/15/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848451573 |
|
| 12/24/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$150.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848409547 |
|
| 12/09/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$12280.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848409545 |
|
| 12/09/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1200.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848409393 |
|
| 12/09/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$65.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848409137 |
|
| 06/14/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$810.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848409119 |
|
| 08/13/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$6780.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848409117 |
|
| 07/15/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$21240.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848409115 |
|
| 09/20/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$60.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848408439 |
|
| 03/08/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3100.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848408309 |
|
| 02/11/2021 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$12240.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
848408307 |
|
| 12/23/2021 |
Research |
Cash or cash equivalent |
Biological |
$370.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
793081313 |
|
| 12/23/2021 |
Research |
Cash or cash equivalent |
Biological |
$680.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
793081311 |
|
| 08/13/2021 |
Research |
Cash or cash equivalent |
Biological |
$20.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
793081307 |
|
| 08/13/2021 |
Research |
Cash or cash equivalent |
Biological |
$180.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
793081305 |
|
| 06/14/2021 |
Research |
Cash or cash equivalent |
Biological |
$120.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
793081299 |
|
| 05/10/2021 |
Research |
Cash or cash equivalent |
Biological |
$275.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
793081297 |
|
| 05/10/2021 |
Research |
Cash or cash equivalent |
Biological |
$340.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
793081295 |
|
| 04/12/2021 |
Research |
Cash or cash equivalent |
Biological |
$55.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
793081293 |
|
| 03/08/2021 |
Research |
Cash or cash equivalent |
Biological |
$120.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
793081291 |
|
| 02/11/2021 |
Research |
Cash or cash equivalent |
Biological |
$100.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
793081289 |
|
| 01/13/2021 |
Research |
Cash or cash equivalent |
Biological |
$160.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
793081287 |
|
| 12/03/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$10980.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747840229 |
|
| 12/28/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$8960.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747840043 |
|
| 12/03/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$585.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747840041 |
|
| 11/09/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$580.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747829171 |
|
| 11/09/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$15740.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747829163 |
|
| 10/15/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$515.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747798873 |
|
| 10/15/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$27600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747798869 |
|
| 09/21/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$430.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747776525 |
|
| 09/21/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2320.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747776521 |
|
| 08/17/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$540.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747626525 |
|
| 08/17/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$23380.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747626359 |
|
| 07/09/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$885.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747625727 |
|
| 07/09/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$56380.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747625725 |
|
| 06/15/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$29340.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747621345 |
|
| 06/15/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$520.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747620083 |
|
| 04/13/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1140.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747618933 |
|
| 05/11/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1010.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747618931 |
|
| 03/19/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$150.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747615289 |
|
| 02/20/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$85.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747614949 |
|
| 01/13/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1305.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747614831 |
|
| 02/20/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$100.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
747614825 |
|
| 01/13/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$470.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
743164275 |
|
| 12/28/2020 |
Research |
Cash or cash equivalent |
Biological |
$55.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
724430577 |
|
| 12/03/2020 |
Research |
Cash or cash equivalent |
Biological |
$520.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430571 |
|
| 11/09/2020 |
Research |
Cash or cash equivalent |
Biological |
$1200.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430565 |
|
| 10/19/2020 |
Research |
Cash or cash equivalent |
Biological |
$1220.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430559 |
|
| 09/21/2020 |
Research |
Cash or cash equivalent |
Biological |
$540.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430553 |
|
| 09/21/2020 |
Research |
Cash or cash equivalent |
Biological |
$410.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
724430549 |
|
| 07/13/2020 |
Research |
Cash or cash equivalent |
Biological |
$980.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430543 |
|
| 07/13/2020 |
Research |
Cash or cash equivalent |
Biological |
$55.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
724430537 |
|
| 06/15/2020 |
Research |
Cash or cash equivalent |
Biological |
$320.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430533 |
|
| 05/11/2020 |
Research |
Cash or cash equivalent |
Biological |
$130.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
724430527 |
|
| 05/11/2020 |
Research |
Cash or cash equivalent |
Biological |
$100.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430521 |
|
| 04/13/2020 |
Research |
Cash or cash equivalent |
Biological |
$295.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
724430513 |
|
| 03/19/2020 |
Research |
Cash or cash equivalent |
Biological |
$180.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430507 |
|
| 03/19/2020 |
Research |
Cash or cash equivalent |
Biological |
$280.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
724430503 |
|
| 02/20/2020 |
Research |
Cash or cash equivalent |
Biological |
$440.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
724430497 |
|
| 02/20/2020 |
Research |
Cash or cash equivalent |
Biological |
$350.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
724430491 |
|
| 01/13/2020 |
Research |
Cash or cash equivalent |
Biological |
$1015.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB; ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN THE SECOND-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
724430485 |
|
| 06/15/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$70.00 |
Details |
| Payment from |
Astellas Pharma Inc |
| Payment Record ID |
714550237 |
|
| 05/11/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$320.00 |
Details |
| Payment from |
Astellas Pharma Inc |
| Payment Record ID |
714550235 |
|
| 02/20/2020 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$170.00 |
Details |
| Payment from |
Astellas Pharma Inc |
| Payment Record ID |
714550231 |
|
| 06/17/2019 |
General (Non-Research) |
Cash or cash equivalent |
Food and Beverage |
$23.08 |
Details |
| Payment from |
GE Healthcare |
| Payment Record ID |
698473211 |
|
| 12/12/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$700.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695876841 |
|
| 12/12/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2970.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695876839 |
|
| 11/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$675.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695872471 |
|
| 11/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4180.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695872381 |
|
| 10/24/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4000.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695825851 |
|
| 10/10/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$335.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695825847 |
|
| 10/10/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2565.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695825725 |
|
| 10/24/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$240.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695825723 |
|
| 10/24/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2005.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695825721 |
|
| 10/24/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$150.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695824421 |
|
| 10/10/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$260.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695824247 |
|
| 04/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3630.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771841 |
|
| 07/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$890.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771801 |
|
| 02/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$7825.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771791 |
|
| 04/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$7700.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771675 |
|
| 07/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$760.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771671 |
|
| 03/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$7305.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771665 |
|
| 03/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$6180.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771307 |
|
| 02/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$6175.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771305 |
|
| 06/13/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$615.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771303 |
|
| 04/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$60.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771301 |
|
| 02/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$60.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771299 |
|
| 04/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5175.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771189 |
|
| 06/13/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4580.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771185 |
|
| 08/22/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$375.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771177 |
|
| 02/07/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3730.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771175 |
|
| 08/22/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$370.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771173 |
|
| 07/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$370.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771065 |
|
| 07/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3620.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771061 |
|
| 03/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$360.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771059 |
|
| 02/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$30.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771051 |
|
| 05/16/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2700.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695771049 |
|
| 06/13/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$260.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770957 |
|
| 03/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2340.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770947 |
|
| 08/22/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2135.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770943 |
|
| 06/13/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2015.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770841 |
|
| 02/07/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$185.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770835 |
|
| 04/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1375.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770725 |
|
| 05/16/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1330.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770723 |
|
| 05/16/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1330.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770721 |
|
| 07/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1270.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770713 |
|
| 02/07/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$12100.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770615 |
|
| 02/07/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1195.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770611 |
|
| 04/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$110.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770605 |
|
| 08/22/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$20.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770295 |
|
| 05/16/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$130.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770291 |
|
| 02/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1205.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770177 |
|
| 07/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$780.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770047 |
|
| 02/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$9925.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770027 |
|
| 03/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$9835.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695770025 |
|
| 05/16/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4055.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
695769931 |
|
| 10/10/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2490.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
673783785 |
|
| 10/24/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4610.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
673783433 |
|
| 08/22/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$365.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
673783431 |
|
| 12/12/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1385.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
673783429 |
|
| 07/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1285.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
673783427 |
|
| 11/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1435.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
673783425 |
|
| 05/16/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2050.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
672388227 |
|
| 04/18/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4950.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
672388223 |
|
| 06/13/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1095.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
672388217 |
|
| 03/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$10665.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
672125373 |
|
| 02/28/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4360.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
671895931 |
|
| 02/21/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$9905.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
671895919 |
|
| 02/07/2019 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3535.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
671894949 |
|
| 12/12/2019 |
Research |
Cash or cash equivalent |
Biological |
$1170.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
639754287 |
|
| 11/21/2019 |
Research |
Cash or cash equivalent |
Biological |
$655.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
639754285 |
|
| 10/24/2019 |
Research |
Cash or cash equivalent |
Biological |
$1310.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
639754283 |
|
| 10/10/2019 |
Research |
Cash or cash equivalent |
Biological |
$110.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
639754281 |
|
| 08/22/2019 |
Research |
Cash or cash equivalent |
Biological |
$370.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
639754279 |
|
| 07/18/2019 |
Research |
Cash or cash equivalent |
Biological |
$185.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
639754277 |
|
| 06/13/2019 |
Research |
Cash or cash equivalent |
Biological |
$760.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
639754275 |
|
| 02/07/2019 |
Research |
Cash or cash equivalent |
Biological |
$1900.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of REGN2810 Anti-PD-1 in Japanese Patients With Advanced Malignancies |
| Clinical Trials Gov ID |
NCT03233139 |
| Payment Record ID |
639754273 |
|
| 09/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$25685.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
610461503 |
|
| 08/02/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$15100.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
610185079 |
|
| 08/23/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$18260.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
610185061 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$18700.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
610139585 |
|
| 12/20/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3700.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
609950467 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2190.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
609913167 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3685.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
609861065 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1600.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
609861061 |
|
| 11/01/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$7340.00 |
Details |
| Payment from |
PFIZER INC. |
| Payment Record ID |
609752407 |
|
| 12/20/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$23975.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604788589 |
|
| 12/20/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$6405.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604787463 |
|
| 12/20/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$13900.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604787353 |
|
| 12/20/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1295.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604787351 |
|
| 12/20/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$100.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604787273 |
|
| 11/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1255.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604786351 |
|
| 11/01/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1410.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604783933 |
|
| 11/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1295.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604783927 |
|
| 11/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1200.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604783925 |
|
| 11/01/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$11265.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604783923 |
|
| 11/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$10045.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604783921 |
|
| 11/01/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$460.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604783459 |
|
| 11/01/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3345.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604783321 |
|
| 11/01/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1645.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604782065 |
|
| 09/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$870.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604668141 |
|
| 09/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$570.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604668041 |
|
| 09/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$480.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604668039 |
|
| 09/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4180.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604668037 |
|
| 09/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$33835.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604668035 |
|
| 09/27/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$330.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604667013 |
|
| 08/23/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$7950.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604629437 |
|
| 08/23/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$520.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604625355 |
|
| 08/23/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2585.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604625349 |
|
| 08/23/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$115.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604625275 |
|
| 07/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1270.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604556203 |
|
| 07/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$975.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604555997 |
|
| 07/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5375.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604555899 |
|
| 07/12/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$260.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604555889 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$20.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604532167 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$20.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604532165 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$20.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604532163 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$120.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604532151 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$110.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604532105 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3055.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604531915 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$165.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604531865 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$65.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604531257 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$60.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604531255 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$540.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604531253 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3705.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604531207 |
|
| 06/21/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$275.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604531201 |
|
| 05/10/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$9685.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420893 |
|
| 05/10/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$810.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420887 |
|
| 05/10/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$80.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420885 |
|
| 05/10/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$65.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420883 |
|
| 05/10/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5200.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420789 |
|
| 05/10/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$340.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420781 |
|
| 05/17/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$20.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420663 |
|
| 05/17/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$20.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420661 |
|
| 05/17/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420611 |
|
| 05/10/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$480.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420605 |
|
| 05/17/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420543 |
|
| 05/10/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420541 |
|
| 05/17/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$110.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420535 |
|
| 05/17/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$110.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604420437 |
|
| 04/19/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4745.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604393271 |
|
| 04/19/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$10660.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604392627 |
|
| 04/19/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$900.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604391293 |
|
| 02/22/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$8905.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604391289 |
|
| 04/19/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$65.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604391283 |
|
| 04/19/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3965.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604391143 |
|
| 04/19/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$380.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604391033 |
|
| 02/22/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2280.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604391021 |
|
| 02/22/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$225.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604391019 |
|
| 02/22/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$195.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604390887 |
|
| 04/19/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1410.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604390873 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2730.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604315149 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$65.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604315091 |
|
| 01/04/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$960.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604315015 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$900.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604315013 |
|
| 01/04/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5590.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604315009 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5220.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604314967 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$495.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604314965 |
|
| 01/04/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$495.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604314963 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604314953 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604314951 |
|
| 01/04/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$130.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604314895 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$200.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604314835 |
|
| 03/15/2018 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$16185.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
604314773 |
|
| 05/17/2018 |
Research |
Cash or cash equivalent |
Biological |
$1600.00 |
Details |
| Payment from |
Regeneron Pharmaceuticals, Inc. |
| Paymment Research Study |
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Clinical Trials Gov ID |
NCT03430063 |
| Payment Record ID |
577361157 |
|
| 12/14/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$10960.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504813939 |
|
| 11/22/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1215.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504754113 |
|
| 10/18/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$450.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504658133 |
|
| 10/18/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3630.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504658127 |
|
| 10/18/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3185.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504658123 |
|
| 10/18/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$200.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504657923 |
|
| 10/18/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$10660.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504656237 |
|
| 09/14/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$10075.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504476781 |
|
| 09/14/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4290.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504476611 |
|
| 09/14/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3750.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504476231 |
|
| 09/14/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$135.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504476171 |
|
| 08/17/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5940.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504370817 |
|
| 08/17/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2665.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504369497 |
|
| 08/17/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$17615.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504369483 |
|
| 07/13/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4810.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504203459 |
|
| 07/13/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$19370.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504203371 |
|
| 07/06/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1365.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504203361 |
|
| 07/06/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$18525.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504202897 |
|
| 07/13/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$7860.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504201881 |
|
| 07/13/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504201799 |
|
| 07/06/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5040.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
504201789 |
|
| 05/25/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$780.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503950897 |
|
| 05/25/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$6695.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503950891 |
|
| 05/25/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2790.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503949157 |
|
| 04/27/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$5465.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503783705 |
|
| 04/27/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$390.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503783663 |
|
| 04/27/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$2700.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503783659 |
|
| 03/16/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$8850.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503631565 |
|
| 03/16/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$75.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503631555 |
|
| 03/16/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3030.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503631531 |
|
| 02/09/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3330.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503587421 |
|
| 02/09/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$150.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503587009 |
|
| 02/09/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$8775.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503584815 |
|
| 01/12/2017 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$4965.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
503584765 |
|
| 12/12/2016 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$675.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
406482814 |
|
| 12/12/2016 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$270.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
406482804 |
|
| 11/17/2016 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$3045.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
406459580 |
|
| 09/29/2016 |
General (Non-Research) |
Cash or cash equivalent |
Consulting Fee |
$1600.00 |
Details |
| Payment from |
Merck Sharp & Dohme Corporation |
| Payment Record ID |
406018350 |
|
